News

All existing investors participated, including Versant Ventures, ARCH Venture Partners, Prospect Venture Partners, BBT Capital Management/Apothecary Capital, Jafco, PFM, and Altitude Life Science Ventures. The company plans to

China-Biotics, a manufacturer of probiotics products, has reported a net income of $5.67m, or $0.22 per diluted share, for the third quarter ended December 31, 2008, compared to

Net income for the year ended December 31, 2008 was $11.1 million, or $0.87 per fully diluted share, compared to $8.4 million, or $0.72 per diluted share, for

Net income for the year ended December 31, 2008 was $30.8 million, or $0.29 per fully diluted share, compared to a net loss of $15.8 million, or $0.16

For the full year 2008, the company posted net revenues of CHF1.47 billion, an increase of 12%, compared to CHF1.32 billion for the full year 2007. Jean-Paul Clozel,

Diamyd Medical, a biopharmaceutical company, has received approval from the Swedish Medical Products Agency to continue to follow the children who participated in the company’s Phase II study

The new drug application (NDA) is supported by results from a two-year, double-blind, placebo-controlled, randomized Phase III clinical trial of 1,382 men with advanced prostate cancer on androgen

The company expects to raise $320 million in aggregate gross proceeds from the common stock offering. Merrill Lynch & Company is acting as the sole book-runner, with Cowen

BioAlliance Pharma, a specialty pharmaceutical company, has initiated its European marketing application for ondansetron RapidFilm, the fast-dissolving oral film strip formulation of ondansetron. According to the company, this